News
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...
Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.
Our approach to implementing social impact starts with our own purpose, to empower every person and every organisation on the planet to achieve more.
Zacks Investment Research on MSN4d
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Shares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will ...
Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" ...
Zacks Investment Research on MSN5d
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback